Dianthus Therapeutics (DNTH) Operating Leases (2022 - 2025)

Dianthus Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $1.0 million for Q4 2025.

• In Q4 2025, Operating Leases fell 12.98% year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (down 12.98% YoY), while the FY2025 annual figure was $1.0 million, down 12.98% from the prior year.
• Operating Leases for Q4 2025 stood at $1.0 million, down from $1.1 million in the prior quarter.
• The five-year high for Operating Leases was $32.4 million in Q1 2022, with the low at $30000.0 in Q2 2024.
• The 4-year median for Operating Leases is $1.1 million (2025), against an average of $7.5 million.
• The sharpest annual moves came in 2023 and 2025: Operating Leases plunged 99.05% in 2023, then soared 3630.0% in 2025.
• Dianthus Therapeutics' Operating Leases stood at $438000.0 in 2022, then plunged by 61.64% to $168000.0 in 2023, then jumped by 597.02% to $1.2 million in 2024, then declined by 12.98% to $1.0 million in 2025.
• Business Quant data shows DNTH's Operating Leases at $1.0 million in Q4 2025, $1.1 million in Q3 2025, and $1.1 million in Q2 2025.